Clinical Trial

The Effects of Virtual Reality-Based Gamified Rehabilitation in Children With Hemophilia

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 1, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
Hemophilia is an inherited bleeding disorder caused by deficiencies or low levels of clotting factors VIII (hemophilia A) and IX (hemophilia B). It is a chronic disease that negatively affects physical function, mobility, and quality of life by causing damage to joint and muscle structures due to bleeding disorders. Traditional rehabilitation methods can sometimes be boring for children and lead to a loss of motivation. Therefore, there is a need for innovative methods that will increase treatment compliance and improve children's physical activity levels. Virtual reality (VR) technology provides a realistic and interactive environment that enables children to actively participate in the rehabilitation process. Combined with gamification elements, VR offers a fun learning and practice environment that supports the development of motor skills, reduces fear of movement, and can increase motivation for repetitive exercises. This randomized controlled trial will evaluate the effects of virtual reality-based gamified rehabilitation on joint health, pain, posture, gait function, proprioception, and quality of life. Additionally, the contribution of this intervention to changes in activity and participation levels will be demonstrated using the International Classification of Functioning, Disability, and Health (ICF) model. This study has the potential to guide future clinical practice by offering a more enjoyable and effective rehabilitation alternative for children with hemophilia. The widespread adoption of virtual reality-supported programs will be an important step in reducing physical disabilities associated with hemophilia.
Trial Details
NCT Number NCT07200609
Lead Sponsor Hacettepe University
Conditions Hemophilia A Without Inhibitor
Enrollment 20 participants
Start Date 2025-11
Primary Completion 2026-04 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-10-01